[A Case of HER2-Positive Esophagogastric Junction Cancer with Perforation Curatively Resected after Neoadjuvant Chemotherapy plus Trastuzumab]

Gan To Kagaku Ryoho. 2016 Jun;43(6):761-4.
[Article in Japanese]

Abstract

A 60-year-old man was diagnosed with adenocarcinoma of the esophagogastric junction with lymph node metastasis along the left gastric artery. The clinical stage was determined to be T4b, N1, M0, Stage IIIB, and a neoadjuvant chemotherapy (NAC)regimen of capecitabine/CDDP plus trastuzumab was selected for treatment. Before 3 courses of chemotherapy, the patient developed perforated gastric cancer. With conservative therapy, we were able to obtain closure of the perforation without affecting the curability of the cancer. We changed the chemotherapy regimen to S-1/CDDP plus trastuzumab, and the patient underwent curative resection.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cisplatin / administration & dosage
  • Drug Combinations
  • Esophagogastric Junction / pathology*
  • Humans
  • Male
  • Neoadjuvant Therapy*
  • Oxonic Acid / administration & dosage
  • Receptor, ErbB-2 / analysis
  • Stomach Diseases / etiology
  • Stomach Diseases / surgery*
  • Stomach Neoplasms / complications
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / surgery
  • Tegafur / administration & dosage
  • Trastuzumab / administration & dosage
  • Treatment Outcome

Substances

  • Drug Combinations
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab
  • Cisplatin